Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its full year 2024 financial results announcement for March 26, 2025, after U.S. markets close. The company will host an analyst conference call on March 27, 2025, at 8:00 am ET (12 noon GMT).
A live audio webcast of the conference call will be available to investors, media, and the public. The webcast recording will remain accessible for 90 days after the event on Alvotech's investor website. Additionally, the company will host a local investor event in Icelandic at Sæmundargata 15-19, Reykjavik, on March 27, 2025, at 4:00 pm GMT.
Alvotech (NASDAQ: ALVO), una azienda biotecnologica globale focalizzata nello sviluppo di farmaci biosimilari, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 per il 26 marzo 2025, dopo la chiusura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica per analisti il 27 marzo 2025, alle 8:00 ET (12:00 GMT).
Una trasmissione audio in diretta della conferenza telefonica sarà disponibile per investitori, media e pubblico. La registrazione della trasmissione rimarrà accessibile per 90 giorni dopo l'evento sul sito web per investitori di Alvotech. Inoltre, l'azienda ospiterà un evento locale per investitori in islandese presso Sæmundargata 15-19, Reykjavik, il 27 marzo 2025, alle 16:00 GMT.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en el desarrollo de medicamentos biosimilares, ha programado el anuncio de sus resultados financieros para el año completo 2024 para el 26 de marzo de 2025, después del cierre de los mercados estadounidenses. La empresa llevará a cabo una conferencia telefónica para analistas el 27 de marzo de 2025, a las 8:00 am ET (12:00 GMT).
Una transmisión de audio en vivo de la conferencia telefónica estará disponible para inversores, medios de comunicación y el público. La grabación de la transmisión permanecerá accesible durante 90 días después del evento en el sitio web para inversionistas de Alvotech. Además, la empresa organizará un evento local para inversores en islandés en Sæmundargata 15-19, Reikiavik, el 27 de marzo de 2025, a las 4:00 pm GMT.
알보텍 (NASDAQ: ALVO), 바이오시밀러 의약품 개발에 주력하는 글로벌 생명공학 회사는 2024 회계연도 전체 재무 결과 발표를 2025년 3월 26일 미국 시장 마감 후로 예정했습니다. 이 회사는 2025년 3월 27일 오전 8시 ET (GMT 12시)에 애널리스트 컨퍼런스 콜을 개최할 예정입니다.
컨퍼런스 콜의 생중계 오디오 웹캐스트는 투자자, 언론 및 일반 대중에게 제공됩니다. 웹캐스트 녹음은 이벤트 이후 90일 동안 알보텍의 투자자 웹사이트에서 접근할 수 있습니다. 또한, 이 회사는 2025년 3월 27일 오후 4시 GMT에 아이슬란드어로 Sæmundargata 15-19, 레이캬비크에서 지역 투자자 이벤트를 개최할 예정입니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale axée sur le développement de médicaments biosimilaires, a prévu l'annonce de ses résultats financiers pour l'année complète 2024 pour le 26 mars 2025, après la fermeture des marchés américains. L'entreprise organisera une conférence téléphonique pour les analystes le 27 mars 2025 à 8h00 ET (12h00 GMT).
Une diffusion audio en direct de la conférence téléphonique sera disponible pour les investisseurs, les médias et le public. L'enregistrement de la diffusion sera accessible pendant 90 jours après l'événement sur le site web des investisseurs d'Alvotech. De plus, l'entreprise organisera un événement local pour les investisseurs en islandais au Sæmundargata 15-19, Reykjavik, le 27 mars 2025 à 16h00 GMT.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung von biosimilaren Arzneimitteln konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das Gesamtjahr 2024 für den 26. März 2025, nach dem Schließen der US-Märkte, angesetzt. Das Unternehmen wird am 27. März 2025 um 8:00 Uhr ET (12:00 Uhr GMT) eine Analystenkonferenzschaltung abhalten.
Ein Live-Audio-Webcast der Konferenzschaltung wird für Investoren, Medien und die Öffentlichkeit verfügbar sein. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf der Investoren-Website von Alvotech zugänglich. Darüber hinaus wird das Unternehmen am 27. März 2025 um 16:00 Uhr GMT eine lokale Investorenveranstaltung auf Isländisch in der Sæmundargata 15-19, Reykjavik, veranstalten.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2024, after U.S. markets close on Wednesday, March 26, 2024. Following the release, Alvotech will conduct a conference call for analysts on Thursday, March 27, 2025, at 8:00 am ET (12 noon GMT). Live audio of the conference call will be webcast and available to members of the news media, investors and the general public.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s earnings calendar and can be found here: https://investors.alvotech.com/events/event-details/q4-2024-earnings-full-year. The webcast will be archived and available for replay for 90 days after the event on Alvotech’s investors’ website.
On March 27, 2025, at 4:00 pm GMT, Alvotech will host a local investor event, at Sæmundargata 15-19, Reykjavik. Note that the event will be in Icelandic. Information on how to register to attend in person is available at: https://www.alvotech.is/fjarfestafundur-q4-2024-og-arid.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When will Alvotech (ALVO) release its full year 2024 financial results?
What time is Alvotech's (ALVO) Q4 2024 earnings conference call?
How long will Alvotech's (ALVO) Q4 2024 earnings webcast be available for replay?
Where is Alvotech (ALVO) hosting its local investor event for Q4 2024 results?
